PEPGEN INC. Fair Value Adjustment of Warrants
PEPGEN INC. (PEPG) reported Fair Value Adjustment of Warrants of -$58.00 thousand for the 12-month period ending 2022-12-31, per its 10-K/A filed 2024-03-29.
Discontinued › Cash Flow
us-gaap:FairValueAdjustmentOfWarrants · last filed 2024-03-29
- PEPGEN INC. fair value adjustment of warrants for the quarter ending 2022-12-31 was $0.00.
- PEPGEN INC. fair value adjustment of warrants for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- PEPGEN INC. fair value adjustment of warrants for the quarter ending 2022-06-30 was $0.00.
- PEPGEN INC. fair value adjustment of warrants for the quarter ending 2022-03-31 was -$58.00K.
- PEPGEN INC. fair value adjustment of warrants for fiscal 2022 was -$58.00K, a 129.59% decline from fiscal 2021.
- PEPGEN INC. fair value adjustment of warrants for fiscal 2021 was $196.00K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | -$58.00K 10-K/A · filed 2024-03-29 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2023-08-08 | -$58.00K 10-Q · filed 2023-11-08 | -$120.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$58.00K 10-Q · filed 2023-08-08 | -$120.00K derived: sum of 3 quarters · filed 2023-08-08 | -$55.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$58.00K 10-Q · filed 2023-05-11 | -$120.00K derived: sum of 2 quarters · filed 2023-05-11 | -$55.00K derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $3.00K derived: sum of 2 quarters · filed 2023-03-23 | $196.00K 10-K · filed 2023-03-23 | |
| 2021-09-30 | $65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $258.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $193.00K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |